ROLE OF CHEMOKINES AND CHEMOKINE RECEPTORS IN AIDS
趋化因子和趋化因子受体在艾滋病中的作用
基本信息
- 批准号:2463669
- 负责人:
- 金额:--
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:
- 资助国家:美国
- 起止时间:至
- 项目状态:未结题
- 来源:
- 关键词:HIV infections chemokine clinical research cytokine receptors disease /disorder proneness /risk enzyme activity gene frequency gene mutation genetic mapping genetic polymorphism helper T lymphocyte human genetic material tag human immunodeficiency virus 1 human population genetics human subject immunogenetics nucleic acid sequence virus receptors
项目摘要
In all well-characterized epidemics there are individuals in the
population that respond differently to the infectious agent. Although
resistance to infection is the most common variable phenotype,
variation in disease outcomes has also been observed. Epidemiologic
studies have shown that inherited factors are involved in the risk of
mortality to infectious agents. The HIV-1 epidemic presents a critical
challenge to apply current genetic techniques to the study of host
genetic variation for infection and susceptibility to infection. This
problem is confounded in the studies of HIV-1 by the rapid rate of
evolution of the virus.
The CKR5 gene serves as a secondary receptor on CD4+ T lymphocytes for
certain strains of human immunodeficiency virus. The CKR5 gene was
mapped to human chromosome 3p21, and a 32 base pair deletion allele
(CKR5delta32) was identified that is present at a frequency of
approximately 0.10 in the Caucasian population. An examination of 1955
patients included among six well-characterized AIDS cohort studies
revealed that 18 deletion homozygotes occur exclusively among 612
exposed HIV-1-antibody negative individuals (2.8%) and not in 1343
HIV-1-infected individuals. CKR5 deletion heterozygotes (+/delta32)
were significantly elevated among patients that survive HIV-1 infection
for more than 10 years, in some cases twice as frequent as their
occurrence in rapid progressors to AIDS. Survival analysis clearly
shows that disease progression is slower in CKR5 deletion
heterozygotes. The CKR5delta32 deletion may act as a recessive
restriction gene against HIV-1 infection and exerts a dominant
phenotype of delaying progression to AIDS among infected patients. In
addition, we have identified five other alterations in the CKR5 gene,
including four missense alterations in conserved residues, and an amino
acid deletion. These alterations should further add to the
understanding of the role of CKR5 in HIV infection and disease
progression.
在所有特征明确的流行病中,都有一些人
不同的人群对传染源的反应不同。 虽然
对感染的抗性是最常见的可变表型,
还观察到疾病结果的变化。 流行病学
研究表明,遗传因素与
传染源的死亡率。 HIV-1流行病是一个严重的
将现有遗传技术应用于宿主研究的挑战
感染和感染易感性的遗传变异。 这
HIV-1研究中的问题因HIV-1的快速传播而变得混乱
病毒的进化。
CKR 5基因作为CD 4 + T淋巴细胞上的第二受体,
人类免疫缺陷病毒的某些菌株。 CKR 5基因是
定位于人类染色体3 p21,和一个32碱基对缺失等位基因
(CKR 5 δ 32)被鉴定为以
在高加索人群中约为0.10。 1955年的考试
纳入6项特征明确的艾滋病队列研究的患者
结果显示,18个缺失纯合子仅发生在612个
暴露于HIV-1抗体阴性个体(2.8%),1343例未暴露于HIV-1抗体阴性个体(2.8%)
HIV-1感染者。 CKR 5缺失杂合子(+/delta 32)
在HIV-1感染后存活的患者中,
超过10年,在某些情况下,频率是他们的两倍。
发生在艾滋病快速进展者中。 生存分析明确
显示CKR 5缺失的疾病进展较慢
杂合子 CKR 5delta 32缺失可能作为隐性遗传,
限制性基因对HIV-1感染,并发挥显性
在感染患者中延迟进展为AIDS的表型。 在
此外,我们还发现了CKR 5基因中的其他五个变异,
包括保守残基中的四个错义改变,以及一个氨基酸
酸性缺失 这些变化将进一步增加
了解CKR 5在HIV感染和疾病中的作用
进展
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
M DEAN其他文献
M DEAN的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('M DEAN', 18)}}的其他基金
MOLECULAR ANALYSIS OF THE NEVOID BASAL CELL CARCINOMA GENE
痣样基底细胞癌基因的分子分析
- 批准号:
6160940 - 财政年份:
- 资助金额:
-- - 项目类别:
DEVELOPING HIGH RESOLUTION RFLPS FOR HUMAN GENETIC ANALYSIS
开发用于人类遗传分析的高分辨率 RFLPS
- 批准号:
3838461 - 财政年份:
- 资助金额:
-- - 项目类别:
MOLECULAR ANALYSIS OF THE NEVOID BASAL CELL CARCINOMA GENE
痣样基底细胞癌基因的分子分析
- 批准号:
6100840 - 财政年份:
- 资助金额:
-- - 项目类别:
ABC TRANSPORTERS IN HUMAN DISEASE AND DRUG RESISTANCE
人类疾病和耐药性中的 ABC 转运蛋白
- 批准号:
6100857 - 财政年份:
- 资助金额:
-- - 项目类别:
相似国自然基金
Chemokine-Gli2信号环路调控肝癌生长的分子机制及其靶点价值
- 批准号:81660467
- 批准年份:2016
- 资助金额:39.0 万元
- 项目类别:地区科学基金项目
相似海外基金
Atypical Chemokine Receptors orchestrate changes in vascular patterning during fibrotic liver disease via Endothelial-to-Mesenchymal Transition.
非典型趋化因子受体通过内皮-间质转化协调纤维化肝病期间血管模式的变化。
- 批准号:
MR/Y013751/1 - 财政年份:2024
- 资助金额:
-- - 项目类别:
Research Grant
Potential role of chemokine (C-C motif) ligand 18 in the development of obese asthma and Type 2 inflammation using epidemiological and experimental studies
使用流行病学和实验研究发现趋化因子(C-C 基序)配体 18 在肥胖哮喘和 2 型炎症发展中的潜在作用
- 批准号:
23K09664 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
Knockdown of AdipoR2 Compromises Adiponectin’s Anti-inflammatory Actions by Mainly Promoting a Pro-inflammatory Chemokine and Cytokine Secretory Profile in THP-1 Macrophages
AdipoR2 的敲低主要通过促进 THP-1 巨噬细胞中促炎趋化因子和细胞因子的分泌特征来损害脂联素的抗炎作用
- 批准号:
493138 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Structure-based inhibition of chemokine signaling in the inflamed pancreas
基于结构的炎症胰腺趋化因子信号传导抑制
- 批准号:
10656002 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Targeting Age-Activated Proinflammatory Chemokine Signaling by CCL2/11 to Enhance Skeletal Muscle Regeneration in Aging
通过 CCL2/11 靶向年龄激活的促炎趋化因子信号传导以增强衰老过程中的骨骼肌再生
- 批准号:
478877 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Operating Grants
Mechanism of metastatic control by chemokine receptor ACKR3
趋化因子受体ACKR3控制转移的机制
- 批准号:
23K06639 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Grant-in-Aid for Scientific Research (C)
PET Imaging to Evaluate a Novel Chemokine Antagonist to Protect Synapses in ADRD
PET 成像评估新型趋化因子拮抗剂保护 ADRD 突触
- 批准号:
10818903 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Development of A Dual Chemokine CCL2/CCL5 Neutralizing Single-domainAntibody for Treating Non-alcoholic Steatohepatitis
双趋化因子 CCL2/CCL5 中和单域抗体的开发用于治疗非酒精性脂肪性肝炎
- 批准号:
10761039 - 财政年份:2023
- 资助金额:
-- - 项目类别:
Integrated Imaging Tools for Intercellular Chemokine Signalling
用于细胞间趋化因子信号转导的集成成像工具
- 批准号:
10706896 - 财政年份:2023
- 资助金额:
-- - 项目类别:














{{item.name}}会员




